Stroke: the dashed hopes of neuroprotection.
Hill
Michael D
MD
Hotchkins Brain Institute, University of Calgary, Foothills Hospital, Calgary, ABT2N 2T9, Canada. michael.hill@calgaryhealthregion.ca
D000208:Acute Disease; D001241:Aspirin / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000627:therapeutic use*; D002339:Carotid Arteries / Q000601:surgery; D000077144:Clopidogrel; D004176:Dipyridamole / Q000627:therapeutic use; D005060:Europe; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D015607:Stents; D020521:Stroke / Q000188:drug therapy* / Q000517:prevention & control; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use
D001557:Benzenesulfonates; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D018696:Neuroprotective Agents; D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; C120851:disufenton sodium; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin